cav2 2 channel blocker x conotoxin gvia Search Results


  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • conotoxin gvia  (Bachem)
    86
    Bachem conotoxin gvia
    Conotoxin Gvia, supplied by Bachem, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/conotoxin gvia/product/Bachem
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    conotoxin gvia - by Bioz Stars, 2023-12
    86/100 stars
    		  Buy from Supplier
    cav2 2 blocker  (Alomone Labs)
    86
    Alomone Labs cav2 2 blocker
    Cav2 2 Blocker, supplied by Alomone Labs, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cav2 2 blocker/product/Alomone Labs
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cav2 2 blocker - by Bioz Stars, 2023-12
    86/100 stars
    		  Buy from Supplier
    cav2 2 blockers  (Pain Therapeutics)
    86
    Pain Therapeutics cav2 2 blockers
    A CRMP-2 peptide suppresses the <t>CaV2.2-CRMP-2</t> interaction in vitro. (a) Cartoon illustrating the main hypothesis. (b) Summary of normalized binding of CaV2.2 to 15 amino acid peptides (overlapping by 12 amino acids) encompassing full-length CRMP-2 overlaid with spinal cord lysates. Sequence of peptide #96, designated CBD3, is shown. (c) Immunoprecipitation (IP) with CRMP-2 antibody from spinal cord lysates in the presence of scramble or CBD3 peptides failed to pull-down CaV2.2 (top) and CRMP-2 (middle) but not β-tubulin (bottom). (d) Sensorgram of CBD3 (1/3/5 μM; solid traces) or scramble peptide (1/3/5 μM; dotted traces) binding to immobilized cytosolic loop 1 (L1) and distal C-terminus (Ct-dis) of CaV2.2. Dissociation was monitored for 4 min. RU, resonance units. (e) In vitro binding of L1-GST and Ct-dis-GST fusion proteins to CRMP-2 in the presence of scramble or CBD3 peptides (10 μM). CRMP-2 bound to L1 and Ct-dis was probed with a CRMP-2 antibody. CaV2.2 is detected on the surface of CAD cells (f) but not when CBD3 fused to GFP is over-expressed (g). Below, normalized surface intensity (SI) between arrows demarcating the surface of cells shown in f and g. (h) Summary of the percent of cells exhibiting surface CaV2.2 expression (n>100). (i) Immunoblots of biotinylated (surface) fractions of CAD cells expressing vector (scramble), an N-terminal region of CRMP-2 (CBD1), or CBD3 probed with a CaV2.2 antibody (n=3). (j) Top, voltage protocol. Bottom, exemplar traces from hippocampal neurons overexpressing vector (EGFP), CRMP-2 or CRMP-2 + CBD3. (k) Peak current density (pA/pF), at +10 mV, for CRMP-2- and CRMP-2 + CBD3-transfected neurons. *, p <0.05 versus CRMP-2, Student's t-test.
    Cav2 2 Blockers, supplied by Pain Therapeutics, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/cav2 2 blockers/product/Pain Therapeutics
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    cav2 2 blockers - by Bioz Stars, 2023-12
    86/100 stars
    		  Buy from Supplier
    calcium channel cav2 2  (Expression Systems Inc)
    86
    Expression Systems Inc calcium channel cav2 2
    A CRMP-2 peptide suppresses the <t>CaV2.2-CRMP-2</t> interaction in vitro. (a) Cartoon illustrating the main hypothesis. (b) Summary of normalized binding of CaV2.2 to 15 amino acid peptides (overlapping by 12 amino acids) encompassing full-length CRMP-2 overlaid with spinal cord lysates. Sequence of peptide #96, designated CBD3, is shown. (c) Immunoprecipitation (IP) with CRMP-2 antibody from spinal cord lysates in the presence of scramble or CBD3 peptides failed to pull-down CaV2.2 (top) and CRMP-2 (middle) but not β-tubulin (bottom). (d) Sensorgram of CBD3 (1/3/5 μM; solid traces) or scramble peptide (1/3/5 μM; dotted traces) binding to immobilized cytosolic loop 1 (L1) and distal C-terminus (Ct-dis) of CaV2.2. Dissociation was monitored for 4 min. RU, resonance units. (e) In vitro binding of L1-GST and Ct-dis-GST fusion proteins to CRMP-2 in the presence of scramble or CBD3 peptides (10 μM). CRMP-2 bound to L1 and Ct-dis was probed with a CRMP-2 antibody. CaV2.2 is detected on the surface of CAD cells (f) but not when CBD3 fused to GFP is over-expressed (g). Below, normalized surface intensity (SI) between arrows demarcating the surface of cells shown in f and g. (h) Summary of the percent of cells exhibiting surface CaV2.2 expression (n>100). (i) Immunoblots of biotinylated (surface) fractions of CAD cells expressing vector (scramble), an N-terminal region of CRMP-2 (CBD1), or CBD3 probed with a CaV2.2 antibody (n=3). (j) Top, voltage protocol. Bottom, exemplar traces from hippocampal neurons overexpressing vector (EGFP), CRMP-2 or CRMP-2 + CBD3. (k) Peak current density (pA/pF), at +10 mV, for CRMP-2- and CRMP-2 + CBD3-transfected neurons. *, p <0.05 versus CRMP-2, Student's t-test.
    Calcium Channel Cav2 2, supplied by Expression Systems Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/calcium channel cav2 2/product/Expression Systems Inc
    Average 86 stars, based on 1 article reviews
    Price from $9.99 to $1999.99
    calcium channel cav2 2 - by Bioz Stars, 2023-12
    86/100 stars
    		  Buy from Supplier

    Image Search Results


    A CRMP-2 peptide suppresses the CaV2.2-CRMP-2 interaction in vitro. (a) Cartoon illustrating the main hypothesis. (b) Summary of normalized binding of CaV2.2 to 15 amino acid peptides (overlapping by 12 amino acids) encompassing full-length CRMP-2 overlaid with spinal cord lysates. Sequence of peptide #96, designated CBD3, is shown. (c) Immunoprecipitation (IP) with CRMP-2 antibody from spinal cord lysates in the presence of scramble or CBD3 peptides failed to pull-down CaV2.2 (top) and CRMP-2 (middle) but not β-tubulin (bottom). (d) Sensorgram of CBD3 (1/3/5 μM; solid traces) or scramble peptide (1/3/5 μM; dotted traces) binding to immobilized cytosolic loop 1 (L1) and distal C-terminus (Ct-dis) of CaV2.2. Dissociation was monitored for 4 min. RU, resonance units. (e) In vitro binding of L1-GST and Ct-dis-GST fusion proteins to CRMP-2 in the presence of scramble or CBD3 peptides (10 μM). CRMP-2 bound to L1 and Ct-dis was probed with a CRMP-2 antibody. CaV2.2 is detected on the surface of CAD cells (f) but not when CBD3 fused to GFP is over-expressed (g). Below, normalized surface intensity (SI) between arrows demarcating the surface of cells shown in f and g. (h) Summary of the percent of cells exhibiting surface CaV2.2 expression (n>100). (i) Immunoblots of biotinylated (surface) fractions of CAD cells expressing vector (scramble), an N-terminal region of CRMP-2 (CBD1), or CBD3 probed with a CaV2.2 antibody (n=3). (j) Top, voltage protocol. Bottom, exemplar traces from hippocampal neurons overexpressing vector (EGFP), CRMP-2 or CRMP-2 + CBD3. (k) Peak current density (pA/pF), at +10 mV, for CRMP-2- and CRMP-2 + CBD3-transfected neurons. *, p <0.05 versus CRMP-2, Student's t-test.

    Journal: Nature medicine

    Article Title: Suppression of inflammatory and neuropathic pain by uncoupling CRMP-2 from the presynaptic Ca 2+ channel complex

    doi: 10.1038/nm.2345

    Figure Lengend Snippet: A CRMP-2 peptide suppresses the CaV2.2-CRMP-2 interaction in vitro. (a) Cartoon illustrating the main hypothesis. (b) Summary of normalized binding of CaV2.2 to 15 amino acid peptides (overlapping by 12 amino acids) encompassing full-length CRMP-2 overlaid with spinal cord lysates. Sequence of peptide #96, designated CBD3, is shown. (c) Immunoprecipitation (IP) with CRMP-2 antibody from spinal cord lysates in the presence of scramble or CBD3 peptides failed to pull-down CaV2.2 (top) and CRMP-2 (middle) but not β-tubulin (bottom). (d) Sensorgram of CBD3 (1/3/5 μM; solid traces) or scramble peptide (1/3/5 μM; dotted traces) binding to immobilized cytosolic loop 1 (L1) and distal C-terminus (Ct-dis) of CaV2.2. Dissociation was monitored for 4 min. RU, resonance units. (e) In vitro binding of L1-GST and Ct-dis-GST fusion proteins to CRMP-2 in the presence of scramble or CBD3 peptides (10 μM). CRMP-2 bound to L1 and Ct-dis was probed with a CRMP-2 antibody. CaV2.2 is detected on the surface of CAD cells (f) but not when CBD3 fused to GFP is over-expressed (g). Below, normalized surface intensity (SI) between arrows demarcating the surface of cells shown in f and g. (h) Summary of the percent of cells exhibiting surface CaV2.2 expression (n>100). (i) Immunoblots of biotinylated (surface) fractions of CAD cells expressing vector (scramble), an N-terminal region of CRMP-2 (CBD1), or CBD3 probed with a CaV2.2 antibody (n=3). (j) Top, voltage protocol. Bottom, exemplar traces from hippocampal neurons overexpressing vector (EGFP), CRMP-2 or CRMP-2 + CBD3. (k) Peak current density (pA/pF), at +10 mV, for CRMP-2- and CRMP-2 + CBD3-transfected neurons. *, p <0.05 versus CRMP-2, Student's t-test.

    Article Snippet: However, the use of CaV2.2 blockers in pain therapeutics is limited by side effects that result from inhibited physiological functions of these channels.

    Techniques: In Vitro, Binding Assay, Sequencing, Immunoprecipitation, Expressing, Western Blot, Plasmid Preparation, Transfection